In patients with coronary artery disease angiotensin-converting enzyme (ACE) inhibitors reduce cardiovascular mortality and myocardial infarction rate, most probably by producing beneficial action on functionally damaged endothelial cells and by reversing atherosclerotic process to some point. The gene discussed is ACE; the disease is myocardial infarction.